HomepageATHA • NASDAQ
add
Athira Pharma
Vorige slotkoers
$ 0,59
Dag-range
$ 0,56 - $ 0,60
Jaar-range
$ 0,41 - $ 4,30
Beurswaarde
21,74 mln. USD
Gem. volume
305,48K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 25,49 mln. | -27,25% |
Netto inkomsten | -28,74 mln. | 12,83% |
Netto winstmarge | — | — |
Winst per aandeel | — | — |
EBITDA | -25,25 mln. | 27,44% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 68,86 mln. | -60,19% |
Totale activa | 86,25 mln. | -53,30% |
Totale passiva | 28,66 mln. | -4,25% |
Totaal aandelenvermogen | 57,58 mln. | — |
Uitstaande aandelen | 38,67 mln. | — |
Koers-boekwaardeverhouding | 0,40 | — |
Rendement op activa | -64,54% | — |
Rendement op kapitaal | -88,74% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -28,74 mln. | 12,83% |
Operationele kasstroom | -23,02 mln. | 4,01% |
Kasstroom uit beleggingen | 18,04 mln. | -12,81% |
Kasstroom uit financiering | 12,00K | — |
Nettomutatie in liquide middelen | -4,97 mln. | -50,94% |
Vrije kasstroom | -10,13 mln. | 13,86% |
Over
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Opgericht
2011
Hoofdvestiging
Website
Werknemers
66
